Biogen, Inc. (BIIB)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Biogen, Inc. (BIIB)
Go deeper and ask any question about BIIB
Company Performance
Current Price
as of Sep 18, 2024$197.59
P/E Ratio
24.89
Market Cap
$28.78B
Description
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerBIIB
- Price$197.59-0.31%
Trading Information
- Market Cap$28.78B
- Float99.19%
- Average Daily Volume (1m)794,027
- Average Daily Volume (3m)980,173
- EPS$7.97
Company
- Revenue$9.29B
- Rev Growth (1yr)0.09%
- Net Income$583.60M
- Gross Margin70.05%
- EBITDA Margin34.48%
- EBITDA$811.20M
- EV$38.77B
- EV/Revenue4.17
- P/E24.89
- P/S3.10